{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:06:45Z","timestamp":1793509605387,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fanconi anemia (FA) is caused by mutations affecting FANC genes involved in DNA repair, with nearly 20% of FA patients harboring nonsense mutations. Ataluren (PTC124) is a translational read-through-inducing drug (TRID) already approved in Europe that has a well-established safety profile even in pediatric patients. Amlexanox, an anti-inflammatory drug, also promotes read-through of premature stop codons caused by nonsense mutations. We compared ataluren and amlexanox in rescuing FANCA, FANCC and FANCF protein synthesis in lymphoblastoid cell lines and fibroblasts obtained from FA patients with nonsense mutations. While ataluren restored all FANC protein levels, amlexanox was partially effective only on FANCA. Notably, the rescue of FANC proteins resulted in a significant downregulation of p53. Moreover, unlike amlexanox, ataluren remarkably improved cell viability and reduced chromosomal aberrations upon exposure to genotoxic compounds. Amlexanox primarily reduced the signal transducer and activator of transcription 2 (STAT2) phosphorylation. Furthermore, <jats:italic>FANCA<\/jats:italic>-mutated fibroblasts exhibited a higher frequency of micronuclei formation as well as lower lamin B1 expression compared to their gene-edited counterpart re-expressing wild-type <jats:italic>FANCA<\/jats:italic>. Interestingly, ataluren significantly limited the generation of micronuclei in nonsense-mutated primary <jats:italic>FANCC<\/jats:italic> fibroblasts, restoring lamin B1 expression. This study represents a milestone of drug development for FA as it paves the way for clinical development of TRIDs, indicating ataluren as a promising approach to address the genetic instability and reduce the risk of malignant transformation in FA cells. Moreover, these results highlight the importance of a reliable experimental pipeline to assess whether minimal protein rescue via translational read-through can yield meaningful phenotypic rescue.<\/jats:p>","DOI":"10.1038\/s41420-025-02571-0","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T15:44:30Z","timestamp":1750520670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9275-8019","authenticated-orcid":false,"given":"Anca Manuela","family":"Hristodor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Baldisseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-5311","authenticated-orcid":false,"given":"Giovanni","family":"Micheloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Frattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fioredda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7248","authenticated-orcid":false,"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-4487","authenticated-orcid":false,"given":"Valentino","family":"Bezzerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2571_CR1","doi-asserted-by":"crossref","unstructured":"Fang C-B, Wu H-T, Zhang M-L, Liu J, Zhang G-J. Fanconi anemia pathway: mechanisms of breast cancer predisposition development and potential therapeutic targets. Front. Cell Dev Biol. 2020;8.","DOI":"10.3389\/fcell.2020.00160"},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.exphem.2015.08.013","volume":"43","author":"Z Abdul-Sater","year":"2015","unstructured":"Abdul-Sater Z, Cerabona D, Potchanant ES, Sun Z, Enzor R, He Y, et al. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. Experimental Hematol. 2015;43:1031\u201346.e1012.","journal-title":"Experimental Hematol"},{"key":"2571_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cell.2013.06.007","volume":"154","author":"EM Hatch","year":"2013","unstructured":"Hatch EM, Fischer AH, Deerinck TJ, Hetzer MW. Catastrophic nuclear envelope collapse in cancer cell micronuclei. Cell. 2013;154:47\u201360.","journal-title":"Cell"},{"key":"2571_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"2571_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.stem.2012.05.013","volume":"11","author":"R Ceccaldi","year":"2012","unstructured":"Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, et al. Bone marrow failure in fanconi anemia is triggered by an exacerbated p53\/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11:36\u201349.","journal-title":"Cell Stem Cell"},{"key":"2571_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00062752-200301000-00011","volume":"10","author":"GC Bagby","year":"2003","unstructured":"Bagby GC. Genetic basis of Fanconi anemia. Current Opin. Hematol. 2003;10:68\u201376.","journal-title":"Current Opin. Hematol"},{"key":"2571_CR7","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062\u2013D1067.","journal-title":"Nucleic Acids Res"},{"key":"2571_CR8","doi-asserted-by":"publisher","first-page":"12353","DOI":"10.1073\/pnas.1615548113","volume":"113","author":"N Siddiqui","year":"2016","unstructured":"Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. Proc Natl Acad. Sci. USA. 2016;113:12353\u20135.","journal-title":"Proc Natl Acad. Sci. USA"},{"key":"2571_CR9","doi-asserted-by":"crossref","unstructured":"Bezzerri V, Api M, Allegri M, Fabrizzi B, Corey SJ, Cipolli M. Nonsense suppression therapy: new hypothesis for the treatment of inherited bone marrow failure syndromes. Int J Mol Sci. 2020,21.","DOI":"10.3390\/ijms21134672"},{"key":"2571_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/hum.2010.067","volume":"22","author":"T Goldmann","year":"2011","unstructured":"Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. PTC124-Mediated translational readthrough of a nonsense mutation causing usher syndrome type 1C. Human Gene Ther. 2011;22:537\u201347.","journal-title":"Human Gene Ther."},{"key":"2571_CR11","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1096\/fj.13-240044","volume":"28","author":"M Li","year":"2014","unstructured":"Li M, Andersson-Lendahl M, Sejersen T, Arner A. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment. FASEB J. 2014;28:1593\u20139.","journal-title":"FASEB J"},{"key":"2571_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3892\/ijmm.2013.1601","volume":"33","author":"H Yu","year":"2014","unstructured":"Yu H, Liu X, Huang J, Zhang Y, Hu R, Pu J. Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome. Int. J. Mol. Med. 2014;33:729\u201335.","journal-title":"Int. J. Mol. Med"},{"key":"2571_CR13","doi-asserted-by":"publisher","first-page":"e1198","DOI":"10.1002\/mgg3.1198","volume":"8","author":"X Liu","year":"2020","unstructured":"Liu X, Zhang Y, Zhang B, Gao H, Qiu C. Nonsense suppression induced readthrough of a novel PAX6 mutation in patient-derived cells of congenital aniridia. Mol Genet Genom. Med. 2020;8:e1198.","journal-title":"Mol Genet Genom. Med"},{"key":"2571_CR14","doi-asserted-by":"crossref","unstructured":"Cipolli M, Boni C, Penzo M, Villa I, Bolamperti S, Baldisseri E, et al. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells. Br J Haematol. 2023;204:292\u2013305.","DOI":"10.1111\/bjh.19134"},{"key":"2571_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2217\/cer-2020-0095","volume":"9","author":"C Campbell","year":"2020","unstructured":"Campbell C, Barohn RJ, Bertini E, Chabrol B, Comi GP, Darras BT, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp. Eff. Res. 2020;9:973\u201384.","journal-title":"J Comp. Eff. Res"},{"key":"2571_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN, Tulinius M, Buccella F, Morgenroth LP, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp. Eff. Res. 2020;9:341\u201360.","journal-title":"J Comp. Eff. Res"},{"key":"2571_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1183\/09031936.00120910","volume":"38","author":"M Wilschanski","year":"2011","unstructured":"Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir. J. 2011;38:59\u201369.","journal-title":"Eur Respir. J"},{"key":"2571_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","volume":"19","author":"MW Konstan","year":"2020","unstructured":"Konstan MW, VanDevanter DR, Rowe SM, Wilschanski M, Kerem E, Sermet-Gaudelus I, et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). J Cyst. Fibros. 2020;19:595\u2013601.","journal-title":"J Cyst. Fibros"},{"key":"2571_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-58","volume":"7","author":"S Gonzalez-Hilarion","year":"2012","unstructured":"Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J. Rare Dis. 2012;7:58.","journal-title":"Orphanet J. Rare Dis"},{"key":"2571_CR20","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","volume":"137","author":"VS Atanasova","year":"2017","unstructured":"Atanasova VS, Jiang Q, Prisco M, Gruber C, Pi\u00f1\u00f3n Hofbauer J, Chen M, et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2017;137:1842\u20139.","journal-title":"J Invest Dermatol"},{"key":"2571_CR21","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2013-01-479733","volume":"122","author":"R Peffault de Latour","year":"2013","unstructured":"Peffault de Latour R, Porcher R, Dalle JH, Aljurf M, Korthof ET, Svahn J, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013;122:4279\u201386.","journal-title":"Blood"},{"key":"2571_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ajh.25025","volume":"93","author":"V Bezzerri","year":"2018","unstructured":"Bezzerri V, Bardelli D, Morini J, Vella A, Cesaro S, Sorio C, et al. Ataluren-driven restoration of Shwachman-Bodian-Diamond syndrome protein function in Shwachman-Diamond syndrome bone marrow cells. Am J. Hematol. 2018;93:527\u201336.","journal-title":"Am J. Hematol"},{"key":"2571_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11091","volume":"7","author":"S Jaber","year":"2016","unstructured":"Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F. p53 downregulates the Fanconi anaemia DNA repair pathway. Nature Commun. 2016;7:11091.","journal-title":"Nature Commun"},{"key":"2571_CR24","doi-asserted-by":"publisher","first-page":"a026070","DOI":"10.1101\/cshperspect.a026070","volume":"6","author":"AB Williams","year":"2016","unstructured":"Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med. 2016;6:a026070.","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2571_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mrfmmm.2009.01.013","volume":"668","author":"AD Auerbach","year":"2009","unstructured":"Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4\u201310.","journal-title":"Mutat Res"},{"key":"2571_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1542\/peds.67.1.119","volume":"67","author":"J Cervenka","year":"1981","unstructured":"Cervenka J, Arthur D, Yasis C. Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics. 1981;67:119\u201327.","journal-title":"Pediatrics"},{"key":"2571_CR27","doi-asserted-by":"crossref","unstructured":"Phan Van T, Huyen Ton Nu Bao T, Leya M, Zhou Z, Jeong H, Lim C-W, et al. Amlexanox attenuates LPS-induced neuroinflammatory responses in microglial cells via inhibition of NF-\u03baB and STAT3 signaling pathways. Sci Rep. 2024;14.","DOI":"10.1038\/s41598-024-53235-5"},{"key":"2571_CR28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/ph16071034","volume":"16","author":"N Benslimane","year":"2023","unstructured":"Benslimane N, Miressi F, Loret C, Richard L, Nizou A, Pyromali I, et al. Amlexanox: readthrough induction and nonsense-mediated mRNA Decay Inhibition in a Charcot\u2013Marie\u2013tooth model of hiPSCs-derived neuronal cells harboring a nonsense mutation in GDAP1 gene. Pharmaceuticals. 2023;16:1034.","journal-title":"Pharmaceuticals"},{"key":"2571_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103515","volume":"70","author":"J Eintracht","year":"2021","unstructured":"Eintracht J, Forsythe E, May-Simera H, Moosajee M. Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein, ciliogenesis and function in patient fibroblasts. EBioMedicine. 2021;70:103515.","journal-title":"EBioMedicine"},{"key":"2571_CR30","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood-2003-01-0114","volume":"102","author":"C Dufour","year":"2003","unstructured":"Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, B\u00e9ka\u2019ssy AN, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood. 2003;102:2053\u20139.","journal-title":"Blood"},{"key":"2571_CR31","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/mc.22240","volume":"54","author":"A Epanchintsev","year":"2015","unstructured":"Epanchintsev A, Shyamsunder P, Verma RS, Lyakhovich A. IL-6, IL-8, MMP-2, MMP-9 are overexpressed in Fanconi anemia cells through a NF-\u03baB\/TNF-\u03b1 dependent mechanism. Mol Carcinogenesis. 2015;54:1686\u201399.","journal-title":"Mol Carcinogenesis"},{"key":"2571_CR32","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.3390\/ijms21134721","volume":"21","author":"M M\u00f6ller","year":"2020","unstructured":"M\u00f6ller M, Wasel J, Schmetzer J, Wei\u00df U, Meissner M, Schiffmann S, et al. The specific IKK\u03b5\/TBK1 inhibitor amlexanox suppresses human melanoma by the inhibition of autophagy, NF-\u03baB and MAP kinase pathways. International J. Mol. Sci. 2020;21:4721.","journal-title":"International J. Mol. Sci."},{"key":"2571_CR33","doi-asserted-by":"crossref","unstructured":"Zhao P, Sun X, Liao Z, Yu H, Li D, Shen Z, et al. The TBK1\/IKK\u03b5 inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis. JCI Insight 2022;7.","DOI":"10.1172\/jci.insight.155552"},{"key":"2571_CR34","doi-asserted-by":"crossref","unstructured":"C\u00f3rdoba-David G, Garc\u00eda-Gim\u00e9nez J, Cardoso Castelo-Branco R, Carrasco S, Cannata P, Ortiz A, et al. Crosstalk between TBK1\/IKK\u03b5 and the type I interferon pathway contributes to tubulointerstitial inflammation and kidney tubular injury. Front Pharmacol. 2022;13.","DOI":"10.3389\/fphar.2022.987979"},{"key":"2571_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s12276-020-0416-y","volume":"52","author":"A Basit","year":"2020","unstructured":"Basit A, Cho M-G, Kim E-Y, Kwon D, Kang S-J, Lee J-H. The cGAS\/STING\/TBK1\/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Experimental Mol. Med. 2020;52:643\u201357.","journal-title":"Experimental Mol. Med"},{"key":"2571_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ebiom.2016.05.005","volume":"8","author":"C Br\u00e9gnard","year":"2016","unstructured":"Br\u00e9gnard C, Guerra J, D\u00e9jardin S, Passalacqua F, Benkirane M, Laguette N. Upregulated LINE-1 activity in the fanconi anemia cancer susceptibility syndrome leads to spontaneous pro-inflammatory cytokine production. EBioMedicine. 2016;8:184\u201394.","journal-title":"EBioMedicine"},{"key":"2571_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156081","volume":"161","author":"J Canar","year":"2023","unstructured":"Canar J, Darling K, Dadey R, Gamero AM. The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance. Cytokine. 2023;161:156081.","journal-title":"Cytokine"},{"key":"2571_CR38","doi-asserted-by":"crossref","unstructured":"Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed 2023;4.","DOI":"10.1186\/s43556-023-00151-1"},{"key":"2571_CR39","doi-asserted-by":"publisher","first-page":"14277","DOI":"10.1074\/jbc.M709731200","volume":"283","author":"CE McCoy","year":"2008","unstructured":"McCoy CE, Carpenter S, P\u00e5lsson-Mcdermott EM, Gearing LJ, O\u2019Neill LAJ. Glucocorticoids inhibit IRF3 phosphorylation in response to toll-like receptor-3 and -4 by targeting TBK1 activation. Journal Biol. Chem. 2008;283:14277\u201385.","journal-title":"Journal Biol. Chem"},{"key":"2571_CR40","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.biochi.2013.06.024","volume":"95","author":"C Capanni","year":"2013","unstructured":"Capanni C, Bruschi M, Columbaro M, Cuccarolo P, Ravera S, Dufour C, et al. Changes in vimentin, lamin A\/C and mitofilin induce aberrant cell organization in fibroblasts from Fanconi anemia complementation group A (FA-A) patients. Biochimie. 2013;95:1838\u201347.","journal-title":"Biochimie"},{"key":"2571_CR41","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41418-021-00764-5","volume":"28","author":"A Helbling-Leclerc","year":"2021","unstructured":"Helbling-Leclerc A, Garcin C, Rosselli F. Beyond DNA repair and chromosome instability\u2014Fanconi anaemia as a cellular senescence-associated syndrome. Cell Death Differ. 2021;28:1159\u201373.","journal-title":"Cell Death Differ"},{"key":"2571_CR42","doi-asserted-by":"crossref","unstructured":"Hoelen H, Kleizen B, Schmidt A, Richardson J, Charitou P, Thomas PJ, et al. The primary folding defect and rescue of \u0394F508 CFTR emerge during translation of the mutant domain. PloS ONE. 2010;5.","DOI":"10.1371\/journal.pone.0015458"},{"key":"2571_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0301-472X(02)00782-8","volume":"30","author":"H Hanenberg","year":"2002","unstructured":"Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, Leurs C, et al. Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Experimental Hematol. 2002;30:410\u201320.","journal-title":"Experimental Hematol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02571-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T15:44:32Z","timestamp":1750520672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02571-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not needed, as this study does not involve patients or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"286"}}